A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG) Read more about A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG)
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Read more about A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS Read more about PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS
Upfront Surgical Resection for Osteosarcoma Read more about Upfront Surgical Resection for Osteosarcoma
A Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources Read more about A Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma Read more about A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC Read more about PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma Read more about Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer Read more about A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3) Read more about VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)